Autologous bone marrow derived stem cell therapy in patients with type 2 diabetes mellitus - defining adequate administration methods

Table 7 Insulin dose (U/d) before and after autologous bone marrow derived stem cell therapy in Group I

Patient	Baseline	3 mo	6 mo	12 mo	18 mo	24 mo
1	32	22	16	Nil	Nil	Nil
2	66	55	53	53	50	_
3	30	20	16	14	-	-
4	46	26	20	20	-	-
5	40	18	12	-	-	-
6	48	8	10	-	-	-
7	Lost to FU
Mean ± SE	44 ± 5	25 ± 7	21 ± 7
P value		0.011	0.003